OBJECTIVE: @entity1069 /chronic @entity2371 ( @entity2723 /CPPS) is a disease with an uncertain cause and limited effective treatments. Apremilast (Celgene Corporation, Summit, NJ, USA) is a selective @entity1980 ( @entity1980 ) inhibitor that modulates the immune system. An open-label, one-arm, pilot study was conducted to explore its potential for improving @entity2723 /CPPS symptoms. METHODS: Males >=  18 years of age were treated with 20 mg oral apremilast twice daily for up to 12 weeks. Outcomes were measured with Global Response Assessment (GRA), @entity158 visual analog scale (VAS), @entity1069 Symptom Index (CPSI), Pittsburgh Sleep Quality Index (PSQI), SF-12 mental ( @entity8848 ) and physical (PCS) health-related quality of life subscales, and voiding diaries. Repeated measures and paired t-tests evaluated changes from baseline to end of treatment, and at a final visit 4 weeks off the drug. RESULTS: Seventeen @entity1 (94% Caucasian; mean age 48.2    10 years) were treated (mean 115.8    56.1 doses). Mean VAS (3.4    2.0 vs 1.8    1.7; P = 0.0011), PSQI (9.4    4.4 vs 7.4    4.2; P = 0.037) and CPSI (26.1    5.0 vs 17.2    8.3; P = 0.0016) scores improved from baseline to end of treatment. @entity322 episodes per day improved slightly (P = 0.042). When only those completing at least 8 weeks of treatment were examined (n = 9), significant changes in CPSI, VAS, and PSQI were still observed. At the final visit, 8/9 (88.9%) @entity1 also reported some improvement in @entity158 related to sex. Side-effects were generally mild and well tolerated. CONCLUSION: These results suggest that apremilast may improve @entity2723 /CPPS symptoms with only mild side-effects. However, placebo controlled studies are necessary to determine efficacy.

Apremilast in the Treatment of @entity1069 /Chronic XXXX : A Pilot Study.

@entity1 :: ('9606', 'Species') :: ['men'] @entity8848 :: ('MESH:C537472', 'Disease') :: ['MCS'] @entity1069 :: ('MESH:D053448', 'Disease') :: ['Chronic prostatitis', 'Chronic Prostatitis'] @entity1980 :: ('5141', 'Gene') :: ['phosphodiesterase type 4', 'PDE4'] @entity322 :: ('MESH:D014549', 'Disease') :: ['Incontinence'] @entity2371 :: ('MESH:D017699', 'Disease') :: ['pelvic pain syndrome'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity2723 :: ('MESH:C566991', 'Disease') :: ['CP']
@entity2371 :: (MESH:D017699,Disease) :: ['Pelvic Pain Syndrome']
